Full Text
Full text is available in PDF
Official Journal of Research Center for Gastroenterology and Liver Diseases
e-ISSN 1735-3408
p-ISSN 1735-143X
Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients?
Authors
1Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2Middle East Liver Diseases Center (MELD), Tehran, IR Iran
*Corresponding Author: Middle East Liver Diseases Center (MELD), Tehran, IR Iran. Tel: +98-9128938931, alavian@thc.ir. Email: alavian@thc.ir
Published online:Nov 22, 2014
Article type:Editorial
Received:Nov 21, 2014
Accepted:Nov 22, 2014
How to Cite:Pourhoseingholi MA, Ashtari S, Alavian SM. Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients?. Hepat Mon. 2014;14(11):25540. doi: https://doi.org/10.5812/hepatmon.25540
Abstract
This article does not have abstract.
Copyright
© 2014, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Similar Articles
30
Sep
2010
Which is the IDEAL Peginterferon for Hepatitis C: A Meta-Analysis of both Pegylated Interferons in the Treatment of HCV-Infected Patients
Frank Tacke
Tacke F. Which is the IDEAL Peginterferon for Hepatitis C: A Meta-Analysis of both Pegylated Interferons in the Treatment of HCV-Infected Patients. Hepat Mon. 2010;10(3):. doi:
30
Sep
2010
Efficacy of Peginterferon Alpha-2a vs. 2b for the Treatment of Chronic HCV: Interpretation of Results and Future Prospects
Hossein Khedmat
Khedmat H. Efficacy of Peginterferon Alpha-2a vs. 2b for the Treatment of Chronic HCV: Interpretation of Results and Future Prospects. Hepat Mon. 2010;10(3):. doi:
8
Mar
2017
Comments on “The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3”
Babak Sayad,
Fatemeh Norooznezhad,
Alireza Farokhi
Sayad B, Norooznezhad F, Farokhi A. Comments on “The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3”. Hepat Mon. 2017;17(3):e58720. doi: https://doi.org/10.5812/hepatmon.46588
30
Jun
2004
How to manage side effects of interferon alpha therapy in Chronic Hepatitis C?
Kamran Bagheri Lankarani
Lankarani K. How to manage side effects of interferon alpha therapy in Chronic Hepatitis C?. Hepat Mon. 2004;4(6):. doi:
31
Mar
2006
Efficacy and safety of Interferon-alpha (PDferon B®) and Ribavirin Combination Therapy in patients with Chronic Hepatitis C in Iran
Seyed Moayed Alavian,
Masoud Ahmadzad Asl,
maryam keshvari,
Bita Behnava,
bashir hajibeigi
Alavian SM, Ahmadzad Asl M, keshvari M, Behnava B, hajibeigi B. Efficacy and safety of Interferon-alpha (PDferon B®) and Ribavirin Combination Therapy in patients with Chronic Hepatitis C in Iran. Hepat Mon. 2006;6(1):e92946. doi:
More by these authors
Cited by
- Scopus by DOI: 8
Last Update: 1 week ago
- Scopus by Title: 8
Last Update: 1 week ago
- Scopus by Title (Ref): 8
Last Update: 1 week ago
- CrossRef: 8
Last Update: 7 hours ago
- OpenAlex: 11
Last Update: 2 days ago
- OpenCitations: 9
Last Update: 5 days ago
Comments
Number of Comments:0